Day: August 12, 2025

HOUSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in the development and operation of high-quality producing energy and industrial gas assets, today reported financial and operating results for the three months ended June 30, 2025. MANAGEMENT COMMENTS “U.S. Energy delivered significant progress in the second quarter of 2025 as we advance our transformation into an integrated industrial gas company,” said Ryan Smith, Chief Executive Officer of U.S. Energy. “Our Montana project continues to move forward with disciplined execution across upstream development, infrastructure design, and carbon management planning. The scale and strategic location of the Kevin Dome positions us as a leader in a high-growth segment of the energy sector—one...

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027Company to host conference call and webcast today at 8:00 a.m. ETNEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results...

— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro’s rare metabolic disorder program will be announced by end of 2025 — Ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities  CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic...

YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD Positive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16 Company to host webcast today at 8:30 a.m. ETMORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive...

–Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone– –Company reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation– –Company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study– –Company anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserve lean mass during chronic weight loss management– –Company to host conference call and webcast today at...

WILLIAMSBURG, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (NASDAQ: SOHO), (“Sotherly” or the “Company”), a self-managed and self-administered lodging real estate investment trust (a “REIT”), today reported its consolidated results for the second quarter ended June 30, 2025. The Company’s results include the following*:  Three Months Ended   Six Months Ended  June 30, 2025   June 30, 2024   June 30, 2025   June 30, 2024  ($ in thousands except per share data)     ($ in thousands except per share data)  Total revenues $ 48,794     $ 50,694     $ 97,106     $ 97,243  Net income   1,556       4,664       6,290       5,987  Net income (loss) attributable to common stockholders   (416 )     2,622       2,274       1,962                         EBITDA   12,022       14,292       27,055       25,076  Hotel...

Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024.Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024.Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024.Enters into five-year, $45 million term loan facility with $20 million funded at close.Reaffirms full-year 2025 total revenue guidance of at least $32.0 million.LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial...